Home Ingredients Glucoamylase (Amyloglucosidase / γ-Amylase)
Gut Health

Glucoamylase (Amyloglucosidase / γ-Amylase)

Glucoamylase EC 3.2.1.3 — also known as amyloglucosidase + γ-amylase. Aspergillus niger source
Evidence Level
Limited
3 Clinical Trials
7 Documented Benefits
2/5 Evidence Score

Digestive enzyme (EC 3.2.1.3, also known as amyloglucosidase or gamma-amylase) that hydrolyzes alpha-1,4 and alpha-1,6 glycosidic linkages in starch — releases glucose. Distinguishing from alpha-amylase, which cleaves only alpha-1,4. Aspergillus niger and A. clavatus fungal sources (vegan-compatible). In a sucrase-deficient shrew model of CSID, oral recombinant glucoamylase increased blood glucose and starch digestion. Cross-application: amyloglucosidase is a key component of the LPO three-enzyme oral hygiene system. Honest framing: industrial and animal feed studies are extensive; human clinical research as a standalone supplement remains limited.

Studied Dose Digestive blend: 25-100 mg/dose as a multi-enzyme component. CSID off-label: oral recombinant glucoamylase per specialist guidance.
Active Compound Glucoamylase EC 3.2.1.3 (amyloglucosidase, gamma-amylase); Aspergillus niger + A. clavatus fungal sources.

Benefits

CSID starch digestion

In a sucrase-deficient Suncus murinus shrew model of congenital sucrase-isomaltase deficiency, oral recombinant glucoamylase (ctMGAM) supplementation increased total blood glucose and quantitative starch digestion to glucose. Animal model evidence; clinical specialist guidance required for pediatric CSID applications.

Supported by Trial 1

α-1,4 + α-1,6 glycosidic bond hydrolysis (mechanism)

Glucoamylase hydrolyzes both alpha-1,4 and alpha-1,6 glycosidic linkages in starch — releases glucose. Distinguishing from alpha-amylase, which cleaves only alpha-1,4 linkages. More complete starch digestion than alpha-amylase alone — particularly relevant for amylopectin (the branched starch component containing alpha-1,6 branch points).

Supported by Trial 1, Trial 2

Maltose hydrolysis to glucose

Hydrolyzes maltose and oligosaccharides to free glucose. Complement to brush border maltase activity for individuals with deficient brush border enzyme function.

Supported by Trial 2

Maltase-glucoamylase brush border alternative

Provides an alternative pathway to mucosal MGAM (maltase-glucoamylase) for starch digestion. Complements sucrase-isomaltase activity in cases of brush border enzyme deficiency.

Supported by Trial 1, Trial 2

Three-enzyme oral hygiene system component

Cross-application: amyloglucosidase is a key component of the LPO three-enzyme oral hygiene system (amyloglucosidase + glucose oxidase + LPO). Generates H₂O₂ from polyglucans, which LPO then uses for hypothiocyanite generation. See the Lactoperoxidase entry for oral health applications.

Supported by Trial 1

Honest framing — limited human supplement evidence

Critical limitation: most evidence is in vitro, animal models, enzyme characterization, and industrial applications. Dedicated human clinical trials for digestive supplementation efficacy are limited — direct standalone evidence in humans is largely absent. Position as formulation component rather than standalone hero ingredient.

Supported by Trial 3

Multi-enzyme formulation context

Glucoamylase typically appears in multi-enzyme digestive formulations alongside α-amylase, cellulase, hemicellulase, diastase, β-glucanase, invertase, lactase, and protease. Synergistic carbohydrate digestion across multiple substrate types — practical use is in combination, not as monotherapy.

Supported by Trial 1, Trial 3

Mechanism of action

1

α-1,4 + α-1,6 glycosidic bond hydrolysis

Hydrolyzes both α-1,4 and α-1,6 glycosidic linkages — distinguishing from α-amylase which cleaves only α-1,4. More complete starch digestion, particularly of amylopectin branch points.

2

Starch + maltodextrin to glucose conversion

Converts starch and maltodextrins efficiently to free glucose. Direct enzymatic conversion mechanism.

3

Brush border alternative pathway

Provides alternative to brush border MGAM for individuals with deficient mucosal enzyme function. Particularly relevant in CSID and similar conditions.

4

Aspergillus niger fungal fermentation

Aspergillus niger and A. clavatus fungal fermentation source — vegan-compatible production. Industrial-scale fermentation supports consistent enzyme purity and activity.

5

LPO three-enzyme system H₂O₂ generation

In the LPO three-enzyme oral hygiene system, amyloglucosidase generates glucose from polyglucans. Glucose oxidase then converts glucose to H₂O₂, which LPO uses for hypothiocyanite production. Cascade-driven mechanism for sustained low-level antimicrobial activity.

6

Local GI lumen activity (no systemic absorption)

Acts locally in the GI lumen — no systemic enzyme absorption needed. Activity is on luminal substrate (starch); no concern for systemic bioavailability.

Clinical trials

1
Sucrase-Deficient Shrew CSID Model

Clinical evidence on Glucoamylase (Amyloglucosidase / γ-Amylase) for the indications and outcomes described.

Clinical population described in trial publication.

Nichols BL et al. 2017 (J Pediatr Gastroenterol Nutr 65:e35-e38, doi:10.1097/MPG.0000000000001561). Sucrase-deficient Suncus murinus shrew model of CSID. Oral recombinant glucoamylase (M20, ctMGAM) supplementation increased total blood glucose and quantitative starch digestion to glucose. Animal model evidence.

2
ctMGAM Maltodextrin Hydrolysis Mechanism

CtMGAM rapidly hydrolyzes maltotetraose and maltopentaose to glucose.

Clinical population described in trial publication.

CtMGAM rapidly hydrolyzes maltotetraose and maltopentaose to glucose. Efficiently converts larger maltodextrins. Mechanism characterization supporting digestive enzyme positioning.

3
Animal Feed Industrial Studies

Animal feed and industrial application studies (and others).

Clinical population described in trial publication.

Animal feed and industrial application studies (and others). Extensive non-human evidence base for enzyme efficacy and safety. Most direct human evidence is from CSID rare-disease context rather than general digestive supplementation.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated; food-grade enzyme of fungal origin.
Mild GI upset (rare; transient).
Allergic reactions (rare; fungal-derived — caution for Aspergillus allergies).
Pregnancy/lactation: limited specific data.
Long-term safety: limited human supplementation data — most evidence industrial/animal/in vitro.
Diabetes: starch digestion enhancement may affect postprandial glucose — monitor blood sugar.

Important Drug interactions

Diabetes medications (insulin, metformin, sulfonylureas): theoretical postprandial glucose interaction — monitor glycemia.
Most medications: no documented interactions.
Other digestive enzymes: compatible (often combined).
Anticoagulants: no interactions documented.
Antibiotics: no documented interactions.

More Gut Health Ingredients

Gut Health
Pancrelipase / Pancreatin
Pancrelipase (also called pancreatin) is a standardized blend of three primary pancreatic…
Gut Health
Sunfiber® (Partially Hydrolyzed Guar Gum)
Sunfiber® is the original and most extensively clinically-studied partially hydrolyzed gua…
Gut Health
Peppermint (Mentha × piperita)
Peppermint is a hybrid mint (Mentha aquatica × Mentha spicata) whose leaves and extracted…
Gut Health
PepZinGI® (Zinc-Carnosine for Gut Lining)
PepZinGI® (NutriScience Innovations) is a unique chelate of zinc and L-carnosine in a 1:1…

Frequently asked questions about Glucoamylase (Amyloglucosidase / γ-Amylase)

What is glucoamylase?

Glucoamylase is a digestive enzyme that breaks down starch and maltose into glucose, complementing amylase in carbohydrate digestion. It is a component of digestive-enzyme blends rather than a standalone supplement.

What is glucoamylase used for?

It helps complete the breakdown of carbohydrates, particularly the maltose left after amylase acts, supporting fuller digestion of starchy foods. It is always part of a digestive-enzyme formula.

When should I take glucoamylase?

Take it with meals, especially carbohydrate-rich ones, as part of a digestive-enzyme blend, so it is present as starches are digested.

Is glucoamylase safe?

As a digestive enzyme it is generally well tolerated. People with enzyme allergies or digestive conditions should check with a doctor. It simply assists normal carbohydrate digestion.

What is the recommended dosage of Glucoamylase?

The clinically studied dose is Digestive blend: 25-100 mg/dose as a multi-enzyme component. CSID off-label: oral recombinant glucoamylase per specialist guidance. Always follow the product label and check with a healthcare provider for personal advice.

Is Glucoamylase safe, and does it have side effects?

For most healthy adults, Glucoamylase is well tolerated at studied doses. Reported effects can include: Generally well-tolerated; food-grade enzyme of fungal origin. Mild GI upset (rare; transient). It may also interact with some medications. Glucoamylase is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Glucoamylase interact with any medications?

Possible interactions include: Diabetes medications (insulin, metformin, sulfonylureas): theoretical postprandial glucose interaction — monitor glycemia. Most medications: no documented interactions. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Glucoamylase?

NutraSmarts rates the evidence for Glucoamylase as Limited (2 out of 5). It is backed by 3 clinical trials and 3 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(3 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Ao Z, Quezada-Calvillo R, Sim L, Nichols BL, Rose DR, Sterchi EE, Hamaker BR Evidence of native starch degradation with human small intestinal maltase-glucoamylase (recombinant) FEBS Lett. 2007;581(13):2381-8. doi:10.1016/j.febslet.2007.04.035.PubMedUsed to support: In vitro mechanistic study demonstrating that human maltase-glucoamylase (MGAM) directly degrades native starch granules via α-1,4 glycosidic bond hydrolysis, establishing glucoamylase's role in human small intestinal starch digestion.
  2. Nichols BL, Baker SS, Quezada-Calvillo R Metabolic Impacts of Maltase Deficiencies J Pediatr Gastroenterol Nutr. 2018;66 Suppl 3:S24-S29. doi:10.1097/MPG.0000000000001955.PubMedUsed to support: Clinical review explaining how deficiencies in mucosal maltase/glucoamylase enzymes impair glucose liberation from starch, causing malabsorption; supports CSID starch digestion and maltase-glucoamylase brush border function benefits.
  3. Nichols BL, Avery SE, Quezada-Calvillo R, Kilani SB, Lin AH, Burrin DG, Hodges BE, Chacko SK, Opekun AR, El Hindawy M, Hamaker BR, Oda SI Improved Starch Digestion of Sucrase-deficient Shrews Treated With Oral Glucoamylase Enzyme Supplements J Pediatr Gastroenterol Nutr. 2017;65(2):e35-e42. doi:10.1097/MPG.0000000000001561.PubMedUsed to support: Preclinical study using sucrase-deficient shrews (model for human CSID) showing oral glucoamylase enzyme supplementation significantly improves starch digestion and absorption; directly supports glucoamylase supplementation for CSID starch digestion benefit.